Sequenom upgraded to Outperform from Market Perform at William Blair William Blair upgraded Sequenom (SQNM) to Outperform after its survey indicated a high likelihood of non-invasive prenatal testing moving quickly into the $1B-plus average-risk pregnancy market. The firm also believes Sequenom's agreement last week with Quest Diagnostics (DGX) provides added market coverage.
LabCorp downgraded to Hold from Buy at Deutsche Bank Deutsche Bank downgraded LabCorp (LH) to Hold saying revenue synergies from the Covance (CVD) acquisition are "hard to envision." The firm believes LabCorp is now less of a pure play in the Clinical Labs space and lowered its price target for shares to $115 from $120. Deutsche coupled the downgrade with an upgrade of peer Quest (DGX).